French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) announced on Friday that it has agreed a strategic partnership with Inserm Transfert (on behalf of Inserm, a French public organisation dedicated to human health) and Nantes University.

The collaboration will focus on oncology, inflammation, and autoimmune diseases.

The alliance combines academic research with industrial expertise to translate cutting-edge discoveries into programmes with industrial and therapeutic potential. It builds on the Immunotherapy Innovation Hub in Nantes and aims to expand this collaborative model nationwide.

Under the agreement, Inserm Transfert and Nantes University will lead project identification, giving OSE Immunotherapeutics access to promising programmes from their research units. Selected projects will receive both financial backing and dedicated guidance to support their development.